| | Characteristic | Low expression of ELF3-AS1 | High expression of ELF3-AS1 | |
| | n | 187 | 187 | | | T stage, n (%) | | | 0.002 | | T1 | 107 (28.8%) | 76 (20.5%) | | | T2 | 36 (9.7%) | 59 (15.9%) | | | T3 | 38 (10.2%) | 42 (11.3%) | | | T4 | 3 (0.8%) | 10 (2.7%) | |
| | N stage, n (%) | | | 0.623 | | N0 | 124 (48.1%) | 130 (50.4%) | | | N1 | 1 (0.4%) | 3 (1.2%) | |
| | M stage, n (%) | | | 0.124 | | M0 | 129 (47.4%) | 139 (51.1%) | | | M1 | 0 (0%) | 4 (1.5%) | |
| | Pathologic stage, n (%) | | | 0.003 | | Stage I | 102 (29.1%) | 71 (20.3%) | | | Stage II | 33 (9.4%) | 54 (15.4%) | | | Stage III | 38 (10.9%) | 47 (13.4%) | | | Stage IV | 1 (0.3%) | 4 (1.1%) | |
| | Tumor status, n (%) | | | 0.101 | | Tumor free | 110 (31%) | 92 (25.9%) | | | With tumor | 69 (19.4%) | 84 (23.7%) | |
| | Gender, n (%) | | | 0.008 | | Female | 48 (12.8%) | 73 (19.5%) | | | Male | 139 (37.2%) | 114 (30.5%) | |
| | Race, n (%) | | | 0.037 | | Asian | 70 (19.3%) | 90 (24.9%) | | | Black or African American | 12 (3.3%) | 5 (1.4%) | | | White | 100 (27.6%) | 85 (23.5%) | |
| | Age, n (%) | | | 0.277 | | ≤60 | 83 (22.3%) | 94 (25.2%) | | | >60 | 104 (27.9%) | 92 (24.7%) | |
| | Weight, n (%) | | | 0.272 | | ≤70 | 88 (25.4%) | 96 (27.7%) | | | >70 | 88 (25.4%) | 74 (21.4%) | |
| | Height, n (%) | | | 0.130 | | <170 | 94 (27.6%) | 107 (31.4%) | | | ≥170 | 78 (22.9%) | 62 (18.2%) | | | BMI, n (%) | | | 0.296 | | ≤25 | 84 (24.9%) | 93 (27.6%) | | | >25 | 86 (25.5%) | 74 (22%) | |
| | Residual tumor, n (%) | | | 0.004 | | R0 | 172 (49.9%) | 155 (44.9%) | | | R1 | 3 (0.9%) | 14 (4.1%) | | | R2 | 0 (0%) | 1 (0.3%) | |
| | Histologic grade, n (%) | | | < 0.001 | | G1 | 41 (11.1%) | 14 (3.8%) | | | G2 | 94 (25.5%) | 84 (22.8%) | | | G3 | 47 (12.7%) | 77 (20.9%) | | | G4 | 2 (0.5%) | 10 (2.7%) | |
| | Adjacent hepatic tissue inflammation, n (%) | | | 0.025 | | None | 73 (30.8%) | 45 (19%) | | | Mild | 44 (18.6%) | 57 (24.1%) | | | Severe | 10 (4.2%) | 8 (3.4%) | |
| | Albumin(g/dl), n (%) | | | 0.982 | | <3.5 | 36 (12%) | 33 (11%) | | | ≥3.5 | 118 (39.3%) | 113 (37.7%) | |
| | AFP (ng/ml), n (%) | | | < 0.001 | | ≤400 | 119 (42.5%) | 96 (34.3%) | | | >400 | 18 (6.4%) | 47 (16.8%) | |
| | Prothrombin time, n (%) | | | 0.889 | | ≤4 | 104 (35%) | 104 (35%) | | | >4 | 46 (15.5%) | 43 (14.5%) | |
| | Child-Pugh grade, n (%) | | | 0.176 | | A | 110 (45.6%) | 109 (45.2%) | | | B | 14 (5.8%) | 7 (2.9%) | | | C | 1 (0.4%) | 0 (0%) | |
| | Fibrosis Ishak score, n (%) | | | 0.526 | | 0 | 43 (20%) | 32 (14.9%) | | | 1/2 | 13 (6%) | 18 (8.4%) | | | 3/4 | 15 (7%) | 13 (6%) | | | 5/6 | 45 (20.9%) | 36 (16.7%) | |
| | Vascular invasion, n (%) | | | 0.037 | | No | 114 (35.8%) | 94 (29.6%) | | | Yes | 46 (14.5%) | 64 (20.1%) | |
| | Age, median (IQR) | 63 (53, 69) | 60 (51, 68) | 0.239 |
|
|
